Sir,
The recent introduction of polyethylene glycol interferon (PEG-IFN) for treatment of hepatitis C virus (HCV) has led to reports of both widespread and localized dermatological manifestations as side-effects. Widespread manifestations comprise hair loss, pruritus, generalized eczema, hyperpigmentation tongue, vitiligo and cutaneous sarcoidosis (1–4). Localized manifestations include cutaneous ulcerations and cutaneous local necrosis at the inoculation site, with both non-pegylated IFN (5) and PEG-IFN-α-2b (6, 7).

We report here a case of bullous lesion at the inoculation site of PEG-IFN-α-2a in a patient with chronic HCV-correlated hepatopathy.

CASE REPORT

The patient, a 53-year-old woman, was diagnosed with chronic HCV in February 1998. From April 2004, she had undergone PEG-IFN-α-2a treatment by injection with weekly doses of 180 μg. The patient was also given ribavirin orally at 1200 mg daily. In July of the same year, the patient presented with rounded, slightly infiltrated erythematous patches, approximately 3 cm in diameter, at the PEG-IFN-α-2a inoculation site, at the subdeltoid level on both arms. After a few days these manifested bullous detachment (Fig. 1). The lesions were asymptomatic and the patient presented no other skin manifestations. Skin biopsy showed a subepidermic bulla with fibrinous content, oedema and lymphocytic and neutrophilic infiltrates in the papillar derma (Fig. 2). PEG-IFN-α-2a treatment was suspended and topical mometasone furoate treatment initiated. Clinical improvement was achieved after a few weeks and complete regression of the erythematous-bullous manifestations occurred after approximately one month.

DISCUSSION

Combination therapy with interferon and ribavirin for chronic hepatitis C has become increasingly effective, and the introduction of PEG-IFN-α in the treatment of chronic HCV has determined an increase in the pharmacokinetic properties of IFN and, consequently, in its antiviral activity.

There are two forms of PEG-IFN-α: PEG-IFN-α-2a and PEG-IFN-α-2b. Peg-IFN-alfa-2a is a bulky branched molecule with a molecular mass of 40kD as compared with Peg-IFN-alfa-2b which is a linear molecule with a molecular mass of 12kD. As a consequence, PEG-IFN-α-2a possesses a greater hemilife and sustains therapeutic levels in the plasma for prolonged periods. This means that PEG-IFN-α-2a alone, or in combination with ribavirin, improves sustained virological responses. Furthermore, therapy with PEG-IFN-α-2a plus ribavirin is associated with better health-related quality of life, because it is associated with significantly less bodily pain, more energy, less disabling fatigue, and fewer limitations in social functioning during the treatment (8).
Dermatological side-effects of PEG-IFN-α-2a reported in the literature comprise only 2 cases of widespread cutaneous manifestation, associated with a localized reaction, and characterized by oedematous erythematous plaques, which were highly exudative, at the injection site (9, 10).

Our case, on the other hand, presented erythematous infiltrated lesions at the injection site, with successive bullous evolution and no other cutaneous manifestations elsewhere on the body. These clinical characteristics, associated with the histology, which revealed a subepidermic bulla and dermopapillary lymphogranulocytic infiltrate without necrosis, vasculitis or vascular microthrombi, leads us to suggest direct toxic action as the cause of the manifestation.

This case is of interest because it is the first to be reported of solely localized cutaneous manifestation with PEG-IFN-α-2a. Its histological characteristics differ from those reported for PEG-IFN-α-2b, in that no vasculitic or necrotic aspects were present. To conclude, it would seem that pegylated IFN determines a wide range of clinical and histological manifestations, which, as yet, are not fully characterized.

REFERENCES